Article: MabCure Inc. Featured in GEN (Genetic Engineering & Biotechnology News).

Company CEO Dr. Amnon Gonenne Contributes Article To September Issue

HASSELT, Belgium -- MabCure, Inc. ("MabCure"), a diagnostic company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, is featured in the September issue of GEN (Genetic Engineering & Biotechnology News). The article, written by MabCure CEO, Dr. Amnon Gonenne, entitled "Searching for Appropriate Cancer Biomarkers," describes how tumor-specific antibodies could positively impact diagnosis, imaging, and therapy.

"Cancer biomarker discovery has been hampered by the heterogeneity of the diseases known as cancer," Dr. Gonenne ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!